Skip to content
Peptigraph home

Tesamorelin

GHRH analog. Tesamorelin is FDA approved (Egrifta); research-chemical versions are not the approved drug.

Also called:tesaEgrifta
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA approved (Egrifta)Prohibited by WADA (S2.2.4)Full legal history

Key facts

How we verify
Class
GHRH analog
Also called
tesa, Egrifta
Vial sizes sold
2 mg, 5 mg, 10 mg, 20 mg
Community-reported sizes
Half-life
11 minutes
subcutaneous (EGRIFTA WR 1.28 mg), in people · FDA label (Egrifta WR)
FDA status
Approved (Egrifta)
Approved
WADA
Prohibited (S2.2.4)
In and out of competition
Everything on Tesamorelin

Tesamorelin guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.Half-lifeWhat is measured, by route, and what is not.StoragePowder and mixed vials: temperature and shelf life.20 mg vialConcentration and unit tables for the 20 mg size.For weight lossWhat research says about Tesamorelin for weight loss.For muscle growthWhat research says about Tesamorelin for muscle growth.For sleepWhat research says about Tesamorelin for sleep.
Vial and dose sizes
2 mg vial5 mg vial10 mg vial30 mg dose
Researched for
heart healthdiabetes

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Tesamorelin: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight loss34010Human RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101
Muscle growthNot in our ledgerNot in our ledger0No graded study for this goal
Sleep101Human RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101
Heart health1306Human RCT evidence, 4 of 4Clinical infectious diseases 2012, PMID 22495074
DiabetesNot in our ledgerNot in our ledger0No graded study for this goal

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Compared with

TesamorelinvsSermorelinGHRH analog next to ghrh analog: evidence, dosing and legal status side by side.Compounded by prescriptionRead the comparison →TesamorelinvsIpamorelinGHRH analog next to ghrp (ghrelin receptor agonist): evidence, dosing and legal status side by side.Not FDA approved · research chemicalRead the comparison →TesamorelinvsCJC-1295GHRH analog next to ghrh analog: evidence, dosing and legal status side by side.Not FDA approved · research chemicalRead the comparison →TesamorelinvsCJC-1295 + IpamorelinGHRH analog next to ghrh + ghrp blend: evidence, dosing and legal status side by side.Not FDA approved · research blendRead the comparison →

Common stacks

Tesamorelin is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Tesamorelin + IpamorelinTesamorelin and Ipamorelin
Tesamorelin + IpamorelinTesamorelin + SermorelinTesamorelin + TirzepatideTesamorelin + CJC-1295 + Ipamorelin

Common questions

Is Tesamorelin FDA approved?

Tesamorelin is FDA approved (Egrifta). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Is Tesamorelin banned in sport?

Yes. Prohibited by WADA (S2.2.4), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: Approved by FDA as Egrifta (original approval 10 Nov 2010), Theratechnologies, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  5. 5The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  6. 6Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
  7. 7EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.